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I. Experimental
General information
All reagents and chemicals were purchased from commercial sources (Aldrich, Across, Fluka) and used without further purification. 4,7-Dibromo-5,6-dioctyloxy-2,1,3-benzothiadiazole, 2,6-bis(trimethyltin)-4,8-dioctyloxy-benzo [1,2-b:3,4-b] dithiophene, and 4,7-di(thiophen-2-yl)-5,6-dioctyloxy-benzo [c] [1,2,5]thiophene were synthesized by already described procedures. a, b, c All reactions were carried out in an argon atmosphere. All solvents were distilled over appropriate drying agent(s) prior to use and were purged with argon. Flash column chromatography was performed on silica gel 60 Å (230-400 mesh). 4 (118 mg, 0.102 mmol) was added. The mixture was heated at 115 °C during 48 h, the mixture was cooled at room temperature, filtered on celite®, the solution was washed with water and dried on sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by column chromatography (dichloromethane/ethyl acetate : 8/2). Recrystallization from chloroform gave the title compound as a yellow powder (613 mg, 97 %). 
4-(5-bromothiazol-2-yl)-7-(thiazol-2-yl)-5,6-dioctyloxy-benzo[c][1,2,5]thiadiazole (1)
NBS (164 mg, 0.923 mmol) was added to a solution of 4,7-di(thiazol-2-yl)-5,6-dioctyloxy-benzo [c] [1,2,5]thiadiazole 3a (516 mg, 0.923 mmol) in chloroform (27 mL) and DMF (27 mL) and the reaction mixture was heated at 60 °C. After 24 h, the mixture was cooled at room temperature, extracted with chloroform, washed with water, and dried on sodium sulfate. The solvent was removed under reduced pressure and recrystallization from chloroform gave the title compound as a light red solid (275 mg, 47 %). 
Compound TaBzBDT
Pd(PPh 3 ) 4 (10 mg, 0.009 mmol) was added to a degassed solution of 4-(5-bromothiazol-2-yl)-7-(thiazol-2-yl)-5,6-dioctyloxy-benzo [c] anhydrous toluene (8 mL). The mixture was heated at 115 °C during 24 h, cooled to room temperature, and filtered on celite®. The solution was washed with water, dried on sodium sulfate, and the solvent was removed under reduced pressure. The crude product was purified by column chromatography (dichloromethane). Precipitation of the resulting product (saturated solution in chloroform) in methanol gave the title compound as an orange-red powder (208 mg, 74 %). 
H NMR
4-(5-bromothiophen-2-yl)-7-(thiophen-2-yl)-5,6-dioctyloxy-benzo[c][1,2,5]thiophene (2)
To a solution of 4,7-di(thiophen-2-yl)-5,6-dioctyloxy-benzo [c] [1,2,5]thiophene 3b (1.42 g, 2.54 mmol) c in chloroform (150 mL) and acetic acid (150 mL), NBS (431 mg, 2.42 mmol) was added and the reaction mixture was stired at r.t. in the dark. After 16 h, the mixture was washed with water, extracted with chloroform, dried on sodium sulfate, and filtred. The solvent was removed under reduced pressure and the residue was purified by column chromatography (petroleum ether/dichloromethane : 9/1) to give the product as a light red solid (1.02 g, 66 %) 
Compound TBzBDT
Pd 2 dba 3 (30 mg, 0.033 mmol) and P(o-tolyl) 3 (40 mg, 0.131 mmol) were added to a degassed solution of 4-(5-bromothiophen-2-yl)-7-(thiophen-2-yl)-5,6-dioctyloxy-benzo [c] [1,2,5]thiadiazole 4b (500 mg, 0.786 mmol) and 2,6-bis(trimethyltin) -4,8-dioctyloxy-benzo[1,2-b:3,4-b] Wavelength (nm) Normalized absorbance (a.u.) V.
IV. DFT calculations
